We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.

Canada markets closed

Theratechnologies Inc. (TH.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
2.1700+0.0200 (+0.93%)
At close: 03:59PM EST
Full screen
Previous Close2.1500
Open2.1200
Bid2.1800 x 0
Ask2.1900 x 0
Day's Range2.1000 - 2.2000
52 Week Range1.2200 - 6.4800
Volume20,292
Avg. Volume83,473
Market Cap106.768M
Beta (5Y Monthly)1.61
PE Ratio (TTM)N/A
EPS (TTM)-1.6700
Earnings DateFeb 26, 2024 - Mar 01, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.43
  • Baystreet

    Stocks in play: Theratechnologies Inc.

    Today announced receipt of the 2023 Industrial Research Sectoral Group (RSRI) Innovation Award from ...

  • GlobeNewswire

    Theratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation Award

    Honor awarded last night recognizes Theratechnologies and Prof. Borhane Annabi for advancing preclinical development of sudocetaxel zendusortide for treatment of triple-negative breast cancerMONTREAL, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of the 2023 Industrial Research Sectoral Group (RSR

  • GlobeNewswire

    Theratechnologies Announces Closing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement

    This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement datedDecember 16, 2021 to its short form base shelf prospectus dated December 14, 2021. MONTREAL, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi

  • GlobeNewswire

    Theratechnologies Announces Pricing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement

    This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. Common shares priced at US$1.00 per share MONTREAL, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that i

  • GlobeNewswire

    Theratechnologies Announces Proposed Public Offering of Common Shares and Concurrent Private Placement

    This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. MONTREAL, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the launch of a marketed public offering (the “P

  • GlobeNewswire

    Theratechnologies Announces Operational Update

    This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. MONTREAL, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced further changes to its operations that will see

  • GlobeNewswire

    Theratechnologies’ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV

    Data presented at AMCP Nexus 2023 highlight implications for U.S. payers based on cost-effectiveness and improved outcomes This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. MONTREAL, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the

  • GlobeNewswire

    Theratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathon

    - Revised the Minimum Liquidity Covenant for All Times Following October 31, 2023 to be Between US$15 Million and US$20 Million - Minimum Quarterly Revenue Covenant Replaced with Minimum Adjusted EBITDA Covenant - Deleted Prohibition Against Having a Going Concern Note in the Opinion of the Company’s Auditors that Accompanies the Company’s Annual Report This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its

  • GlobeNewswire

    Theratechnologies Presents Data at ID Week Showing Tesamorelin Reduces Visceral Adipose Tissue (VAT) and Liver Fat in People with HIV on Integrase Inhibitors (INSTIs)

    Significant reduction in INSTI-associated VAT accumulation with tesamorelin contrasts with VAT increase in patients taking placebo VAT accumulation observed after 12 months on INSTI-containing regimens, even in the absence of significant weight or body mass index changesResults also show a reduction in hepatic fat fraction in people taking tesamorelin This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its s

  • GlobeNewswire

    Theratechnologies Announces Results from Trogarzo® (Ibalizumab-uiyk) Intramuscular Administration Study

    This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. MONTREAL, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced results from a study evaluating an intramuscula